0.6800 -0.02 (-2.84%)
Pre-market: 7:12AM EST
|Bid||0.6700 x 2200|
|Ask||0.0000 x 3000|
|Day's range||0.6809 - 0.7199|
|52-week range||0.6000 - 2.0000|
|Beta (5Y monthly)||2.70|
|PE ratio (TTM)||N/A|
|Earnings date||10 Mar 2020 - 15 Mar 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||3.75|
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So take a moment...
The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.
Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Trevena, Inc. (TRVN). On November 7, 2017, the Company reported that it had submitted a New Drug Application (“NDA”) for Oliceridine, its lead product candidate. On November 2, 2018, the Company disclosed that it received a response from the Food and Drug Administration (“FDA”) denying the NDA for Oliceridine due to inadequate data to support approval.
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 6 cents. The company's shares closed at $1.55. A year ago, they were trading at $1.98. _____ This story was generated ...
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Trevena, Inc. (NASDAQ:TRVN) shareholders will doubtless be very grateful to see the share price up 164% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share...
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $232,000 in the period. For the year, the company reported ...